South Korean AI cancer diagnostics firm Lunit announced that its subsidiary, Volpara Health, has signed a contract to provide breast cancer screening software to Intermountain Health, one of the largest nonprofit healthcare systems in the western United States. Volpara, acquired by Lunit last May, will supply three of its flagship AI-powered software products: Risk Pathways, Analytics, and Scorecard.
These tools will be utilized across Intermountain Health’s extensive network of 34 hospitals and over 400 clinics, spanning seven states, including Utah, Idaho, and Nevada. The software aims to enhance cancer risk assessment, evaluate breast tissue density, and improve the overall quality of mammography services within the healthcare system.
This contract marks a significant step for Lunit in expanding its footprint in the U.S. healthcare market, particularly in leveraging AI for early cancer detection and improved diagnostic accuracy. The collaboration underscores the growing role of AI in transforming cancer care, with Intermountain Health positioned to benefit from enhanced screening capabilities across its facilities.
